Art Biktarvy denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Quantity Limits to Biktarvy — and Why You Can Appeal

Blue Cross Blue Shield quantity-limit denials for Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) typically reflect plan edits that restrict the number of tablets dispensed per fill or the days' supply per dispensing event. Because Biktarvy is a once-daily single-tablet regimen, quantity-limit denials most often arise when the requested supply (for example, a 90-day fill) exceeds the plan's default dispensing limit, or when a prescription is written with a quantity that triggers an automated edit.

Quantity-limit denials are procedurally appealable. The clinical argument is straightforward: larger supplies support adherence, reduce pharmacy burden, and are consistent with the FDA-approved prescribing information for a maintenance HIV regimen.

## The Federal Appeal Framework

• ACA §2719 External Review: Independent external review is available after internal appeal is exhausted, typically within approximately 180 days of the denial notice.
• ERISA §503 (employer-sponsored plans): Full-and-fair review right with written explanation of plan provisions used.
• Expedited review: If the quantity restriction creates a gap in therapy that would seriously jeopardize your health, invoke expedited review in writing at the time of internal appeal filing — decisions are typically required within 72 hours.

## What to Gather

1. Prescriber letter explaining the requested quantity — should document why the requested supply (days' supply or tablet count) is medically appropriate, citing adherence benefits and consistency with the once-daily dosing regimen. 2. FDA prescribing label — confirms the approved once-daily dosing schedule, which supports the requested supply quantity. 3. Adherence and treatment history — chart notes or pharmacy records demonstrating the established regimen and consistent fills. 4. Diagnosis documentation — records confirming HIV-1 diagnosis and current stable treatment status. 5. BCBS's published quantity-limit policy for Biktarvy — obtain the criteria and address each specifically.

## Criteria-Mapping Structure

| BCBS Quantity-Limit Criterion | How the Request Satisfies It | |---|---| | [Paste each criterion from the plan's quantity-limit policy] | [FDA label reference, prescriber statement, adherence documentation] |

## Next Steps

Contact the plan's pharmacy prior-authorization line first — quantity-limit exceptions for extended supplies (e.g., 90-day fills for maintenance HIV therapy) are routinely granted on prescriber attestation. If that path fails, file a formal written internal appeal with the documentation package above. If denied, external review is available.